trending Market Intelligence /marketintelligence/en/news-insights/trending/u8cgy_jsyl1o96un6c4e0a2 content esgSubNav
In This List

Synthetic Biologics chief medical officer to depart

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Synthetic Biologics chief medical officer to depart

Synthetic Biologics Inc. said Joseph Sliman is looking to terminate his employment as chief medical officer.

Sliman alleges a material reduction in his duties, authorities and responsibilities as a company executive. His employment was due to expire in December.

Synthetic Biologics is reviewing its options to dispute Sliman's attempt to terminate his employment agreement.

The Rockville, Md.-based biotechnology company named Michael Kaleko, who serves as senior vice president of research and development, to take over Sliman's responsibilities on an interim basis.

Synthetic Biologics develops therapeutics designed to preserve the human gut microbiome.